Sánchez, Julio C. http://orcid.org/0000-0002-5140-9397
Alemán, Alexander http://orcid.org/0000-0002-3679-8451
Henao, Juan F. http://orcid.org/0000-0003-4327-2439
Olaya, Juan C. http://orcid.org/0000-0003-3162-2243
Ehrlich, Barbara E. http://orcid.org/0000-0001-9657-9704
Funding for this research was provided by:
Ministerio de Ciencia, Tecnología e Innovación (111080763133)
Technological University of Pereira
Article History
Received: 29 November 2023
Accepted: 5 March 2024
First Online: 2 April 2024
Declarations
:
: This study was approved by the Ethics Committee of Universidad Tecnológica de Pereira (8 May 2018. Code: CBE-SYR-162016) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: BEE is a cofounder of Osmol Therapeutics, a company that is targeting NCS-1 for therapeutic purposes. The other authors declare that there are no conflicts of interest.